These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 38873197)

  • 1. Are all fibrinogen concentrates the same? The effects of two fibrinogen therapies in an afibrinogenemic patient and in a fibrinogen deficient plasma model. A clinical and laboratory case report.
    Goodarzi S; Abu-Hanna J; Harper S; Khan D; Morrow G; Curry N
    Front Med (Lausanne); 2024; 11():1391422. PubMed ID: 38873197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy of Fibrinogen Concentrates in Relation to Cryoprecipitate in Restoring Clot Integrity and Stability against Lysis.
    Whyte CS; Rastogi A; Ferguson E; Donnarumma M; Mutch NJ
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.
    Ross C; Rangarajan S; Karimi M; Toogeh G; Apte S; Lissitchkov T; Acharya S; Manco-Johnson MJ; Srivastava A; Brand B; Schwartz BA; Knaub S; Peyvandi F
    J Thromb Haemost; 2018 Feb; 16(2):253-261. PubMed ID: 29220876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the in vitro effects of three fibrinogen concentrates on clot strength in blood samples from cardiac surgery patients.
    Stolt H; Shams Hakimi C; Singh S; Jeppsson A; Karlsson M
    Acta Anaesthesiol Scand; 2021 Nov; 65(10):1439-1446. PubMed ID: 34368944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency.
    Djambas Khayat C; El Khorassani M; Lambert T; Gay V; Barthez-Toullec M; Lamazure J; Bellon A; Henriet C; Bridey F; Négrier C
    J Thromb Haemost; 2019 Apr; 17(4):635-644. PubMed ID: 30661302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficacy of RiaSTAP after rapid reconstitution.
    Karri JV; Cardenas JC; Johansson PI; Matijevic N; Cotton BA; Wade CE; Holcomb JB
    J Surg Res; 2014 Aug; 190(2):655-61. PubMed ID: 24602482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for a phase III, non-inferiority, randomised comparison of a new fibrinogen concentrate versus cryoprecipitate for treating acquired hypofibrinogenaemia in bleeding cardiac surgical patients: the FIBRES trial.
    Karkouti K; Callum J; Rao V; Heddle N; Farkouh ME; Crowther MA; Scales DC
    BMJ Open; 2018 Apr; 8(4):e020741. PubMed ID: 29678987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation as a novel strategy for resolution of congenital afibrinogenemia in a pediatric patient.
    Corrales-Medina FF; Miloh T; O'Farrell C; Andrews DM; Tekin A; De Angulo G
    J Thromb Haemost; 2020 Dec; 18(12):3232-3235. PubMed ID: 32890454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of In Vivo Administration of Fibrinogen Concentrate Versus Cryoprecipitate on Ex Vivo Clot Degradation in Neonates Undergoing Cardiac Surgery.
    Downey LA; Moiseiwitsch N; Nellenbach K; Xiang Y; Brown AC; Guzzetta NA
    Anesth Analg; 2024 Aug; ():. PubMed ID: 39116012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Replacement Therapy for Traumatic Coagulopathy: Does the Fibrinogen Source Matter?
    Morrow GB; Carlier MSA; Dasgupta S; Craigen FB; Mutch NJ; Curry N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
    He S; Johnsson H; Zabczyk M; Hultenby K; Cao H; Blombäck M
    Br J Haematol; 2013 Mar; 160(6):806-16. PubMed ID: 23360261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates.
    Blasi A; Patel VC; Spanke ENHE; Adelmeijer J; Stamouli M; Zamalloa A; Corcoran E; Calvo A; Fernandez J; Bernal W; Lisman T
    Liver Int; 2022 Feb; 42(2):435-443. PubMed ID: 34894081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of two human fibrinogen concentrates to treat dilutional coagulopathy in vitro.
    Haas T; Cushing MM; Asmis LM
    Scand J Clin Lab Invest; 2018 May; 78(3):230-235. PubMed ID: 29446989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
    He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
    Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cryoprecipitate, Factor XIII, and fibrinogen concentrate on hyperfibrinolysis.
    Cushing MM; Fitzgerald MM; Harris RM; Asmis LM; Haas T
    Transfusion; 2017 Oct; 57(10):2502-2510. PubMed ID: 28734018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor XIII levels, clot strength, and impact of fibrinogen concentrate in infants undergoing cardiopulmonary bypass: a mechanistic sub-study of the FIBCON trial.
    Siemens K; Hunt BJ; Parmar K; Taylor D; Salih C; Tibby SM
    Br J Anaesth; 2023 Feb; 130(2):175-182. PubMed ID: 36371257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen Concentrate as an Alternative to Cryoprecipitate in a Postcardiopulmonary Transfusion Algorithm in Infants Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial.
    Downey LA; Andrews J; Hedlin H; Kamra K; McKenzie ED; Hanley FL; Williams GD; Guzzetta NA
    Anesth Analg; 2020 Mar; 130(3):740-751. PubMed ID: 31490252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryoprecipitate: no longer the best therapeutic choice in congenital fibrinogen disorders?
    Bevan DH
    Thromb Res; 2009 Dec; 124 Suppl 2():S12-6. PubMed ID: 20109651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congenital afibrinogenemia.
    al-Mondhiry H; Ehmann WC
    Am J Hematol; 1994 Aug; 46(4):343-7. PubMed ID: 8037188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical evaluation of cryoprecipitate for replacement of fibrinogen.
    Sørensen B; Bevan D
    Br J Haematol; 2010 Jun; 149(6):834-43. PubMed ID: 20456356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.